Baird Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $220
Benzinga Newsdesk 7 hours ago
Analyst RatingsNewsPrice Target
Baird analyst Joel Beatty maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and lowers the price target from $246 to $220.
Baird analyst Joel Beatty maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and lowers the price target from $246 to $220.